Serum concentration of sFas and sFasL in healthy HBsAg carriers, chronic viral hepatitis B and C patients

World Journal of Gastroenterology

Volumn 10, Issue 24, 2004, Pages 3650-3653

  Lapinski, Tadeusz Wojciech ^a   Kowalczuk, Oksana ^a   Prokopowicz, Danuta ^a   Chyczewski, Lech ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; FAS ANTIGEN; FAS LIGAND; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; REBETRON; RIBAVIRIN; VIRUS DNA; VIRUS RNA;

ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; INFLAMMATION; MALE; PROTEIN BLOOD LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS CARRIER;

EID: 10244249242     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v10.i24.3650     Document Type: Article

References (21)

1. Wang XZ, Chen XC, Chen YX, Zhang LJ, Li D, Chen FL, Chen ZX, Chen HY, Tao QM. Overexpression of HBxAg in hepatocellular carcinoma and its relationship with Fas/FasL system. World J Gastroenterol 2003; 9: 2671-2675
2. Mita E, Hayashi N. Apoptosis in human diseases: role of Fas system in liver cell injury by viral hepatitis. Rinsho Byori 1997; 45: 477-482
3. Zhao J, Wang S, Xin S, Yi T, Liu P, Zhang L. Expression of CPP32, Fas and Fas ligand and the relationship between their expression and viral antigens in chronic hepatitis. Zhonghua Ganzangbing Zazhi 2000; 8: 233-235
4. Heo J, Baik TH, Kim HH, Kim GH, Kang DH, Song GA, Cho M, Yang US. Serum hepatitis B virus (HBV) DNA levels at different stages of clinical course in patients with chronic HBV infection in an endemic area. J Korean Med Sci 2003; 18: 686-690
5. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Heptology 2003; 37: 1309-1319
6. Yin XM, Ding WX. Death receptor activation-induced hepatocyte apoptosis and liver injury. Curr Mol Med 2003; 3: 491-508
7. Canbay A, Higuchi H, Bronk SF, Taniai M, Sebo TJ, Gores GJ. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 2002; 123: 1323-1330
8. Ehrmann J Jr, Galuszkova D, Ehrmann J, Krc I, Jezdinska V, Vojtesek B, Murray PG, Kolao Z. Apoptosis-related proteins, BCL-2, BAX, FAS, FAS-L and PCNA in liver biopsies of patients with chronic hepatitis B virus infection. Pathol Oncol Res 2000; 6: 130-135
9. Lee MO, Kang HJ, Cho H, Shin EC, Park JH, Kim SJ. Hepatitis B virus X protein induced expression of the Nur77 gene. Biochem Biophys Res Commun 2001; 288: 1162-1168
10. Liaw YF, Tsai SL, Chien RN, Yeh CT, Chu CM. Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology 2000; 32: 604-609
11. Xin S, Zhao J, Wang L. Study on relationship between the apoptosis of hepatocytes and liver fibrosis of chronic viral hepatitis. Zhonghua Shiyan He Linchuang Bingduxue Zazhi 2000; 14 31-33
12. Hahn CS, Cho YG, Kang BS, Lester IM, Hahn YS. The HCV core protein acts as a positive regulator of fas-mediated apoptosis in a human lymphoblastoid T cell line. Virology 2000; 276: 127-137
13. Marusawa H, Hijikata M, Chiba T, Shimotohno K. Hepatitis C virus core protein inhibits Fas- and tumor necrosis factor alpha-mediated apoptosis via NF-kappa B activation. J Virol 1999; 73: 4713-4720
14. Zhu N, Ware CF, Lai MM. Hepatitis C virus core protein enhances FADD-mediated apoptosis and suppresses TRADD signaling of tumor necrosis factor receptor. Virology 2001; 283: 178-187
15. Ghosh AK, Majumder M, Steele R, Meyer K, Ray R, Ray RB. Hepatitis C virus NS5A protein protects against TNF-alpha mediated apoptotic cell death. Virus Res 2000; 67: 173-178
16. Ezelle HJ, Balachandran S, Sicheri F, Polyak SJ, Barber GN. Analyzing the mechanisms of interferon-induced apoptosis using CrmA and hepatitis C virus NS5A. Virology 2001; 281: 124-137
17. Satoh S, Hirota M, Noguchi T, Hijikata M, Handa H, Shimotohno K. Cleavage of hepatitis C virus nonstructural protein 5A by a caspase-like protease (s) in mammalian cells. Virology 2000; 270 476-487
18. Zuckerman E, Zuckerman T, Sahar D, Streichman S, Attias D, Sabo E, Yeshurun D, Rowe J. Bcl-2 and immunoglobulin gene rearrangement in patients with hepatitis C virus infection. Br J Haematol 2001; 112: 364-369
19. Di Martino V, Brenot C, Samuel D, Saurini F, Paradis V, Reynes M, Bismuth H, Feray C. Influence of liver hepatitis C virus RNA and hepatitis C virus genotype on Fas-mediated apoptosis after liver transplantation for hepatitis C. Transplantation 2000; 15: 1390-1396
20. Ozaslan E, Kilicarslan A, Simsek H, Tatar G, Kirazli S. Elevated serum soluble Fas levels in the various stages of hepatitis C virus-induced liver disease. J Int Med Res 2003; 31: 384-391
21. Yoneyama K, Goto T, Miura K, Mikami K, Ohshima S, Nakane K, Lin JG, Sugawara M, Nakamura N, Shirakawa K, Komatsu M, Watanabe S. The expression of Fas and Fas ligand, and the effects of interferon in chronic liver diseases with hepatitis C virus. Hepatol Res 2002; 24: 327-337